Profile data is unavailable for this security.
About the company
Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate, Diazoxide Choline Extended-Release tablets (DCCR), extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), recently completed its Phase 3 development program. DCCR is a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. DCCR’s mode of action with targets in the brain, pancreas and fat tissue has the potential to impact complex diseases like PWS to reduce appetite, reduce food seeking, improve satiety, improve insulin and leptin resistance and reduce body fat. The Company has a Fast-Track designation for DCCR in PWS and an orphan designation for the drug in the United States and the European Union.
- Revenue in USD (TTM)0.00
- Net income in USD-52.03m
- Incorporated1999
- Employees33.00
- LocationSoleno Therapeutics Inc203 Redwood Shores Parkway, Suite 500REDWOOD CITY 94065United StatesUSA
- Phone+1 (650) 213-8444
- Fax+1 (302) 655-5049
- Websitehttps://soleno.life/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dynavax Technologies Corp | 236.15m | 9.22m | 1.45bn | 408.00 | 222.42 | 2.35 | 106.34 | 6.16 | 0.05 | 0.05 | 1.67 | 4.73 | 0.2414 | 0.7769 | 3.24 | 578,796.60 | 0.9427 | 4.16 | 1.02 | 5.71 | 80.34 | 64.83 | 3.91 | 9.19 | 14.10 | -- | 0.265 | 0.00 | -67.86 | 95.19 | -102.18 | -- | -23.03 | -- |
| Morphic Holding Inc | 0.00 | -161.25m | 1.46bn | 124.00 | -- | 2.21 | -- | -- | -3.49 | -3.49 | 0.00 | 13.25 | 0.00 | -- | -- | 0.00 | -28.67 | -22.69 | -29.49 | -24.99 | -- | -- | -- | -258.10 | -- | -- | 0.00 | -- | -99.26 | -31.11 | -157.61 | -- | 13.50 | -- |
| Avadel Pharmaceuticals PLC (ADR) | 55.14m | -156.83m | 1.49bn | 154.00 | -- | 18.99 | -- | 27.00 | -1.86 | -1.86 | 0.6334 | 0.8157 | 0.3573 | -- | 4.80 | 358,058.40 | -101.63 | -40.21 | -172.85 | -47.99 | 95.71 | -- | -284.42 | -374.75 | 2.60 | -14.71 | 0.00 | -- | -- | -22.99 | -16.59 | -- | -- | -- |
| Spyre Therapeutics Inc | 688.00k | -364.23m | 1.52bn | 30.00 | -- | -- | -- | 2,213.25 | -71.35 | -71.35 | 0.0456 | 11.08 | 0.0026 | -- | -- | 22,933.33 | -134.88 | -101.87 | -150.32 | -118.83 | -- | -- | -52,939.68 | -2,949.59 | -- | -- | 0.00 | -- | -61.96 | -25.61 | -304.21 | -- | -- | -- |
| Arcus Biosciences Inc | 237.00m | -231.00m | 1.54bn | 577.00 | -- | 2.17 | -- | 6.49 | -3.10 | -3.10 | 3.07 | 7.78 | 0.1861 | -- | 6.24 | 410,745.20 | -18.14 | -15.85 | -21.35 | -18.25 | -- | -- | -97.47 | -103.46 | -- | -- | 0.00 | -- | 4.46 | 69.54 | -14.98 | -- | 45.01 | -- |
| Neumora Therapeutics Inc | 0.00 | -254.02m | 1.54bn | 120.00 | -- | 3.63 | -- | -- | -2.44 | -2.44 | 0.00 | 2.66 | 0.00 | -- | -- | 0.00 | -60.32 | -- | -63.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.23 | -- | -- | -- |
| Ligand Pharmaceuticals Inc | 118.31m | 96.34m | 1.55bn | 58.00 | 16.44 | 1.91 | 11.70 | 13.07 | 5.23 | 5.23 | 6.52 | 45.00 | 0.1372 | 0.5475 | 4.11 | 2,039,879.00 | 11.17 | 12.32 | 11.98 | 12.99 | 91.82 | 81.65 | 81.43 | 80.32 | 19.51 | -- | 0.00 | -- | -33.09 | -12.18 | 1,131.21 | -17.86 | 42.63 | -- |
| Taro Pharmaceutical Industries Ltd | 610.83m | 45.70m | 1.59bn | 1.55k | 34.79 | 0.8937 | 20.03 | 2.60 | 1.22 | 1.22 | 16.25 | 47.33 | 0.2854 | 1.45 | 2.76 | 393,068.20 | 2.14 | 1.85 | 2.59 | 2.21 | 48.02 | 56.82 | 7.48 | 6.99 | 3.03 | -- | 0.00 | 0.00 | 2.07 | -2.85 | -56.33 | -34.53 | -7.64 | -- |
| Tilray Brands Inc | 743.25m | -351.95m | 1.60bn | 1.60k | -- | 0.4563 | -- | 2.15 | -0.4979 | -0.4979 | 1.04 | 4.34 | 0.1731 | 2.39 | 8.85 | 464,530.00 | -7.61 | -- | -8.38 | -- | 28.01 | -- | -43.98 | -- | 1.18 | 0.2252 | 0.1216 | -- | -0.1986 | -- | -204.67 | -- | -- | -- |
| Supernus Pharmaceuticals Inc | 597.40m | -15.51m | 1.60bn | 652.00 | -- | 1.72 | 23.00 | 2.68 | -0.2843 | -0.2843 | 10.86 | 16.90 | 0.3859 | 0.922 | 4.10 | 916,259.20 | -1.00 | 4.95 | -1.51 | 6.41 | 87.17 | 88.61 | -2.60 | 12.84 | 1.49 | -- | 0.00 | -- | -8.95 | 8.24 | -97.83 | -58.81 | -8.17 | -- |
| Soleno Therapeutics Inc | 0.00 | -52.03m | 1.60bn | 33.00 | -- | 10.73 | -- | -- | -2.68 | -2.68 | 0.00 | 4.30 | 0.00 | -- | -- | 0.00 | -55.24 | -53.90 | -62.26 | -61.85 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -62.00 | -- | -- | -- |
| Harmony Biosciences Holdings Inc | 617.51m | 137.70m | 1.65bn | 246.00 | 12.53 | 3.20 | 10.17 | 2.67 | 2.32 | 2.32 | 10.39 | 9.08 | 0.7906 | 25.72 | 9.34 | 2,510,207.00 | 17.63 | 7.46 | 20.83 | 9.08 | 79.28 | 80.58 | 22.30 | 10.46 | 3.07 | 31.38 | 0.2694 | 0.00 | 32.93 | -- | -28.99 | -- | -25.31 | -- |
| Structure Therapeutics Inc (ADR) | 0.00 | -97.68m | 1.69bn | 111.00 | -- | 3.92 | -- | -- | -2.32 | -2.32 | 0.00 | 9.22 | 0.00 | -- | -- | 0.00 | -27.73 | -- | -29.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -69.62 | -- | -- | -- |
| Kura Oncology Inc | 0.00 | -168.09m | 1.69bn | 142.00 | -- | 3.34 | -- | -- | -2.18 | -2.18 | 0.00 | 6.63 | 0.00 | -- | -- | 0.00 | -34.31 | -26.04 | -36.21 | -27.45 | -- | -- | -- | -- | -- | -- | 0.0182 | -- | -- | -- | -12.36 | -- | -- | -- |
| Edgewise Therapeutics Inc | 0.00 | -105.85m | 1.69bn | 92.00 | -- | 3.16 | -- | -- | -1.53 | -1.53 | 0.00 | 5.73 | 0.00 | -- | -- | 0.00 | -23.52 | -- | -24.25 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.08 | -- | -- | -- |
| Syndax Pharmaceuticals Inc | 0.00 | -240.63m | 1.72bn | 112.00 | -- | 3.51 | -- | -- | -3.22 | -3.22 | 0.00 | 5.79 | 0.00 | -- | -- | 0.00 | -47.99 | -27.90 | -51.84 | -30.15 | -- | -- | -- | -324.34 | -- | -- | 0.00004 | -- | -- | -- | -40.19 | -- | -- | -- |
Data as of May 17 2024. Currency figures normalised to Soleno Therapeutics Inc's reporting currency: US Dollar USD
47.91%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Perceptive Advisors LLCas of 31 Mar 2024 | 3.07m | 9.20% |
| Janus Henderson Investors US LLCas of 31 Mar 2024 | 2.86m | 8.57% |
| Nantahala Capital Management LLCas of 31 Mar 2024 | 2.41m | 7.21% |
| Adage Capital Management LPas of 31 Mar 2024 | 1.94m | 5.82% |
| Avoro Capital Advisor LLCas of 31 Mar 2024 | 1.63m | 4.86% |
| Vestal Point Capital LPas of 31 Mar 2024 | 1.25m | 3.74% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 970.57k | 2.91% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 952.70k | 2.85% |
| Ikarian Capital LLCas of 31 Mar 2024 | 565.41k | 1.69% |
| Wellington Management Co. LLPas of 31 Mar 2024 | 353.48k | 1.06% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
